The pharmaceutical industry is in a dire situation: R&D still produces no more drugs than 10 years ago, while costs have quadrupled in the meantime. Little advances have been made in innovation efficiency. Worse yet, drug development times are unacceptably long, possible drug development targets are waning, and
national healthcare is tightening the cost squeeze. A predictable and efficient pipeline of drug candidates, coupled with a handful of blockbuster drugs, is considered the Holy Grail of pharmaceutical innovation. In this book, the authors develop a case for mastering pharmaceutical innovation focusing on three leading sources of future pharmaceutical
competitiveness:
new technologies…
